8-K: Petros Pharmaceuticals Changes Auditors, Appoints Marcum LLP

Petros Pharmaceuticals has dismissed EisnerAmper LLP and appointed Marcum LLP as its new independent registered public accounting firm, effective January 8, 2024.

Summary

• Petros Pharmaceuticals dismissed EisnerAmper LLP as their independent auditor on January 8, 2024.
• The dismissal was approved by the Audit Committee of the Board of Directors.
• EisnerAmper's reports on the company's financials for 2021 and 2022 did not have any adverse opinions or disclaimers, but did include a going concern paragraph due to net losses and negative cash flows.
• There were no disagreements with EisnerAmper on accounting principles or practices.
• However, material weaknesses in internal controls were identified by management for 2021, 2022 and the first three quarters of 2023.
• These weaknesses included insufficient monitoring and oversight controls, lack of segregation of duties, and inadequate IT access controls.
• Marcum LLP was appointed as the new independent auditor, also effective January 8, 2024.
• Marcum will prepare the report on the company's consolidated financial statements for the year ended December 31, 2023.
• Petros Pharmaceuticals did not consult with Marcum on accounting principles or audit opinions prior to the appointment.

Sentiment

Score: 3

Explanation: The document highlights significant financial concerns, including a going concern paragraph and material weaknesses in internal controls, leading to a negative sentiment.

Positives

• The transition to a new auditor was completed quickly and efficiently.
• EisnerAmper confirmed there were no disagreements on accounting principles or practices.

Negatives

• EisnerAmper's reports included a going concern paragraph, indicating financial instability.
• Material weaknesses in internal controls were identified by management, suggesting potential issues with financial reporting.
• The company has experienced net losses and negative cash flows from operations since inception.

Risks

• The going concern paragraph in EisnerAmper's reports raises concerns about the company's long-term viability.
• Material weaknesses in internal controls could lead to inaccurate financial reporting.
• The company's financial instability may impact its ability to operate effectively.

Future Outlook

The company will rely on Marcum LLP to prepare the report on the company's consolidated financial statements for the year ended December 31, 2023.

Industry Context

Changes in auditors are not uncommon, but the reasons for the change and the presence of a going concern paragraph and material weaknesses in internal controls are concerning. This may raise questions about the company's financial health and governance.

Comparison to Industry Standards

• The presence of a going concern paragraph is a significant red flag, as most companies aim to avoid such qualifications in their audit reports.
• The identification of material weaknesses in internal controls is also concerning, as it suggests a lack of robust financial oversight. This is not typical for established companies.
• Compared to other publicly traded companies, Petros Pharmaceuticals' situation appears to be more precarious due to these issues.

Stakeholder Impact

• Shareholders may be concerned about the company's financial stability and the potential impact on their investment.
• Employees may be concerned about the company's long-term viability and job security.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• Marcum LLP will prepare the report on the company's consolidated financial statements for the year ended December 31, 2023.

Key Dates

Keywords

auditor, accounting, financial statements, internal controls, EisnerAmper, Marcum, going concern, material weaknesses